Australien - Englisch - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - deferasirox, quantity: 180 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; colloidal anhydrous silica; poloxamer; hypromellose; titanium dioxide; macrogol 4000; purified talc; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. deferasirox sandoz is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. deferasirox sandoz is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - deferasirox, quantity: 90 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; colloidal anhydrous silica; poloxamer; hypromellose; titanium dioxide; macrogol 4000; purified talc; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. deferasirox sandoz is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. deferasirox sandoz is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 1560 mg - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - invega hafyera, a 6-month injection, is indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months or the 3-month paliperidone palmitate injectable product following at least one 3-month injection cycle.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 1092 mg - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - invega hafyera, a 6-month injection, is indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months or the 3-month paliperidone palmitate injectable product following at least one 3-month injection cycle.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

norgine pty ltd - macrogol 3350,potassium chloride,sodium bicarbonate,sodium chloride -

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - macrogol 3350 755.68 mg/g (prepared solution contains 6% w/w); potassium chloride 10.55 mg/g; sodium chloride 37.33 mg/g; sodium sulfate 80.62 mg/g - powder for oral solution - 6% w/w - active: macrogol 3350 755.68 mg/g (prepared solution contains 6% w/w) potassium chloride 10.55 mg/g sodium chloride 37.33 mg/g sodium sulfate 80.62 mg/g excipient: ascorbic acid aspartame citric acid lemon flavour ql58817 - glycoprep-c is indicated for bowel emptying and cleansing by means of total gastrointestinal tract perfusion in preparation for gastrointestinal examination (such as colonoscopy, barium enema x-ray examination), prior to intravenous pyelograms (ivp) or colonic surgery.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

carsl consulting - macrogol 3350 13.125 g;  ; potassium chloride 46.6mg; sodium bicarbonate 178.5mg; sodium chloride 350.7mg - powder for oral solution - 13.8 g - active: macrogol 3350 13.125 g   potassium chloride 46.6mg sodium bicarbonate 178.5mg sodium chloride 350.7mg excipient: acesulfame lemon & lime. trusil 463842 - for effective relief from constipation, treatment of chronic constipation. movicol is also effective in resolving faecal impaction, defined as refractory constipation with faecal loading of the rectum and/or colon confirmed by physical examination of abdomen and rectum.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

carsl consulting - macrogol 3350 100 g;  ; potassium chloride 1.015 g; sodium chloride 2.691 g; sodium sulfate 7.5 g;  ; ascorbic acid 4.7 g;  ; sodium ascorbate 5.9 g;   - powder for oral solution - active: macrogol 3350 100 g   potassium chloride 1.015 g sodium chloride 2.691 g sodium sulfate 7.5 g   excipient: acesulfame potassium aspartame lemon flavour v3938-1n1 active: ascorbic acid 4.7 g   sodium ascorbate 5.9 g   - moviprep is used for bowel cleansing prior to any clinical procedure requiring a clean bowel e.g., bowel endoscopy, lower gastrointestinal radiology or digestive tract surgery.

Irland - Englisch - HPRA (Health Products Regulatory Authority)

helsinn birex pharmaceuticals limited - macrogol 3350 - powder for oral solution - 5.9 gram(s) - osmotically acting laxatives; macrogol, combinations

Irland - Englisch - HPRA (Health Products Regulatory Authority)

chanelle medical - macrogol 3350; potassium chloride; sodium chloride; sodium hydrogen carbonate - powder for oral solution in sachet - 13.7 gram(s) - osmotically acting laxatives; macrogol, combinations